The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab

Different peripheral blood parameters have emerged as prognostic biomarkers in breast cancer (BC), but their predictive role in Human Epidermal growth factor Receptor 2 positive (HER2+) advanced BC (aBC) patients receiving dual anti-HER2 blockade remains unclear. We evaluated the impact of the Pan-I...

Full description

Bibliographic Details
Main Authors: Francesca Ligorio, Giovanni Fucà, Emma Zattarin, Riccardo Lobefaro, Luca Zambelli, Rita Leporati, Carmen Rea, Gabriella Mariani, Giulia V. Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
HER2-positive breast cancer
trastuzumab + pertuzumab
PIV
NLR
MLR
PLR
Online Access:https://www.mdpi.com/2072-6694/13/8/1964

Internet

https://www.mdpi.com/2072-6694/13/8/1964

Similar Items